Pitfalls of polymyxin antimicrobial susceptibility testing of Pseudomonas aeruginosa isolated from cystic fibrosis patients
Open Access
- 1 December 2004
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 54 (6) , 1057-1061
- https://doi.org/10.1093/jac/dkh470
Abstract
Objectives and methods: With their potent activity against Gram-negative bacteria, the polymyxins are important alternative antibiotics for cystic fibrosis (CF) patients. A retrospective evaluation of polymyxin activity against 6001 Pseudomonas aeruginosa, 150 Achromobacter xylosoxidans and 506 Stenotrophomonas maltophilia CF isolates was initiated. In addition, we looked at how polymyxin susceptibility testing was affected by the testing method (agar dilution versus microdilution), the agent (polymyxin E versus polymyxin B), incubation time (24 h versus 48 h) and by different interpretative criteria (German DIN, French FSM, British BSAC). Results: Polymyxin B exhibited reasonable activity against P. aeruginosa (MIC90≤2 mg/L), whereas it was less active against A. xylosoxidans (MIC90≤16 mg/L) and S. maltophilia (MIC90≤16 mg/L). During 2000–2002, polymyxin B resistance in P. aeruginosa, S. maltophilia and A. xylosoxidans was found to be 6.7%, 17.0% and 29.9% (corresponding to 12.4%, 20.7% and 35.4% of infected patients), respectively. When the agar dilution method was used, polymyxin E exhibited higher MICs than polymyxin B. The microdilution method produced lower polymyxin MICs than the agar dilution method. Therefore, the microdilution MICs after prolonged incubation (48 h) and the agar dilution MICs of polymyxin B correlated best (AUC of 0.93, r2 of 0.44 and s of 0.83). Conclusions: Polymyxin resistance among common CF pathogens is not rare, thus underlining the necessity of accurate susceptibility testing. When compared with the agar dilution method, it was found that the microdilution method is a valid, rapid and cost effective alternative for the determination of polymyxin activity. The performance of the microdilution method was most reliable after prolonged incubation (48 h) at a susceptibility breakpoint of ≤4 mg/L according to the BSAC guidelines (specificity 91%, sensitivity 89%, 1.5% very major errors).Keywords
This publication has 8 references indexed in Scilit:
- Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosisJournal of Antimicrobial Chemotherapy, 2003
- Survey of resistance of Pseudomonas aeruginosa from UK patients with cystic fibrosis to six commonly prescribed antimicrobial agentsThorax, 2003
- In vitro activity of the aerosolized agents colistin and tobramycin and five intravenous agents against Pseudomonas aeruginosa isolated from cystic fibrosis patients in southwestern GermanyJournal of Antimicrobial Chemotherapy, 2002
- In Vitro Pharmacodynamic Properties of Colistin and Colistin Methanesulfonate against Pseudomonas aeruginosa Isolates from Patients with Cystic FibrosisAntimicrobial Agents and Chemotherapy, 2001
- A ten year review of ColomycinRespiratory Medicine, 2000
- Polymyxin B Sulfate and Colistin: Old Antibiotics for Emerging Multiresistant Gram-Negative BacteriaAnnals of Pharmacotherapy, 1999
- Four years' experience of intravenous colomycin in an adult cystic fibrosis unitEuropean Respiratory Journal, 1998
- Toxicity of Colistin in Cystic Fibrosis PatientsDICP, 1991